Noah Labs is a Berlin-based digital health startup founded in 2021 that develops Noah Labs Ark, a Class IIa medical device software for AI-powered telemonitoring of cardiovascular patients, particularly those with heart failure and hypertension.[1][2][3][7] The platform integrates smart biosensors, external devices, implants, and the AI algorithm Noah Labs Vox—which uses voice analysis for early detection of cardiac decompensation up to two weeks ahead—via a mobile app for patients and a clinician dashboard, enabling remote vital sign tracking, timely interventions, and reduced hospital admissions without in-person visits.[2][3][4][6][7] It serves cardiologists, general practitioners, and patients, solving the problem of inconvenient traditional monitoring for chronic conditions by making care accessible, scalable, and proactive; the company has shown growth through €3M in equity/grant funding from Nina Capital and Adesso Ventures, CE certification, clinical trials, and partnerships like Charité and the American Heart Association.[2][3][7]
Noah Labs was founded in 2021 in Berlin by CEO Oliver Piepenstock and CTO Marcus Hott (also referred to as Marcus), who met at the Entrepreneur First incubator in London.[2][4][7] Marcus, a machine learning expert, drew inspiration from his cardiovascular AI research at Harvard Medical School, recognizing AI's potential in cardiology.[2][4] Oliver brought entrepreneurial experience from a prior successful healthcare startup, highlighting the need for innovative solutions.[2][4] Dr. Leonhard Riehle joined as Co-Founder and Chief Medical Officer in early development.[2] Pivotal moments include shaping the product through cardiologist interviews in a small Berlin office, securing angel investments, achieving CE certification for Noah Labs Ark in February (enabling commercialization), and raising €3M in May from Nina Capital and Adesso Ventures.[2][3][7]
Noah Labs rides the wave of AI-driven digital health and remote patient monitoring (RPM), accelerated by post-pandemic demand for scalable cardiology solutions amid rising chronic disease burdens like heart failure, which affects millions and drives high hospitalization costs.[3][4][5] Timing aligns with regulatory progress (e.g., MDR compliance) and multimodal AI advancements, including voice as a novel biomarker, positioning it ahead of late-stage diagnostics.[4][6][7] Market forces favoring it include aging populations, healthcare labor shortages, and EU/US funding for deep tech health (e.g., ProFIT grants, EIT Health), enabling cost reductions and broader access in underserved areas.[1][7] It influences the ecosystem by pioneering voice-AI integration, partnering with top institutions like Charité and AHA, and contributing to trials that could set standards for proactive, technology-enabled chronic care beyond cardiology.[2][5][7]
Noah Labs is poised to expand Noah Labs Ark globally through ongoing trials, additional funding, and AI enhancements like broader biomarker adoption, targeting 10x better diagnostics for cardiovascular and other chronic conditions.[4][7] Trends like multimodal AI, wearable integration, and value-based care will propel growth, especially with voice tech's scalability via mobile devices.[4][6] Its influence may evolve from niche telemonitoring to preventive platforms, potentially saving lives and cutting costs as partnerships deepen and data from trials validate outcomes—building on its mission to empower longer, healthier lives from a strong Berlin deep-tech foundation.[2][5][7]
Noah Labs has raised $3.0M in total across 1 funding round.
Noah Labs's investors include Nina Capital.
Noah Labs has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $3.0M Seed | Nina Capital |
